Gene · 51135
Papers3,419
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,419
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa. | Biologics | 2025 | 40621493 | PubTator, text mining | PubMed |
| Molecular Design of Novel Protein-Degrading Therapeutics Agents Currently in Clinical Trial. | Pharmaceutics | 2025 | 40574056 | PubTator, text mining | PubMed |
| Synergistic optimizations of efficacy and membrane permeability of IRAK4 inhibitors: identifying new lead compounds for anti-inflammatory therapeutics. | J Enzyme Inhib Med Chem | 2025 | 40536312 | PubTator, text mining | PubMed |
| The Role of Pattern Recognition Receptors in Epigenetic and Metabolic Reprogramming: Insights into Trained Immunity. | J Inflamm Res | 2025 | 40535352 | PubTator, text mining | PubMed |
| Discovery of pyrrolo[2,3-d]pyrimidine derivatives as novel FLT3/IRAK4 inhibitors. | Eur J Med Chem | 2025 | 40532500 | PubTator, text mining | PubMed |
| Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies. | Front Pharmacol | 2025 | 40520205 | PubTator, text mining | PubMed |
| [Clinical phenotype and genotype analysis of neuroinflammation, autoinflammation, splenomegaly and anemia syndrome caused by IRAK4 gene variant]. | Zhonghua Er Ke Za Zhi | 2025 | 40468499 | PubTator, text mining | PubMed |
| Clustering Based on Innate Immunity Reveals Differential Dysregulation Based on Disease Severity in Myelodysplastic Neoplasms. | Hematol Oncol | 2025 | 40397075 | PubTator, text mining | PubMed |
| Discovery of Edecesertib (GS-5718): A Potent, Selective Inhibitor of IRAK4. | J Med Chem | 2025 | 40375634 | PubTator, text mining | PubMed |
| Exosomal non-coding RNAs: gatekeepers of inflammation in autoimmune disease. | J Inflamm (Lond) | 2025 | 40369549 | PubTator, text mining | PubMed |
| Positive Prognostic Overall Survival Impacts of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients. | Cancers (Basel) | 2025 | 40338274 | PubTator, text mining | PubMed |
| Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias. | Sci Transl Med | 2025 | 40333990 | PubTator, text mining | PubMed |
| Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. | Arthritis Rheumatol | 2025 | 40223599 | PubTator, text mining | PubMed |
| The causal effects of 2,821 protein level ratios on non-small cell lung cancer: a two-sample Mendelian randomization study. | Transl Cancer Res | 2025 | 40104726 | PubTator, text mining | PubMed |
| Preliminary results and a theoretical perspective of co‑treatment using a miR‑93‑5p mimic and aged garlic extract to inhibit the expression of the pro‑inflammatory interleukin‑8 gene. | Exp Ther Med | 2025 | 40084194 | PubTator, text mining | PubMed |
| BAP1 Represses Sequential Activation of IRAKs and NF-κB Signaling in Pancreatic Cancer. | Int J Biol Sci | 2025 | 40083694 | PubTator, text mining | PubMed |
| Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults. | Clin Transl Sci | 2025 | 40055981 | PubTator, text mining | PubMed |
| Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC. | Eur J Med Chem | 2025 | 40037062 | PubTator, text mining | PubMed |
| Identification of new candidate drugs in myelodysplastic syndromes with splicing factor mutations by transcriptional profiling and connectivity map analysis. | Br J Haematol | 2025 | 39988885 | PubTator, text mining | PubMed |
| Design, Synthesis, and Biological Evaluation of Aryl Pyrazolopyrimidines as Toll-Like Receptor 7 Agonists. | Chem Biol Drug Des | 2025 | 39887539 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51135/papers?page=6